Cat. No.: HY-50909

Perifosine

(Synonyms: KRX-0401; NSC 639966; D21266)

19 Cited Publications

Customer Review

Based on 19 publication(s) in Google Scholar

Perifosine is an oral Akt inhibitor which inhibits proliferation of different tumor cell lines with IC₅₀s of 0.6-8.9 μM.

For research use only. We do not sell to patients.

Purity: 99.91%
CAS No.: 157716-52-4
Formula: C₂₅H₅₂NO₄P
Molecular Weight:461.66

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Perifosine Chemical Structure

CAS No.: 157716-52-4

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (19)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

Perifosine is an oral Akt inhibitor which inhibits proliferation of different tumor cell lines with IC₅₀s of 0.6-8.9 μM.

IC₅₀ & Target^[1]

Autophagy

All Akt Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	4.17 μM Compound: perifosine	Cytotoxicity against human A549 cells after 24 to 72 hrs by haemocytometry Cytotoxicity against human A549 cells after 24 to 72 hrs by haemocytometry	[PMID: 24900620]
A549	IC₅₀	5.3 μM Compound: 2, OPP	Inhibition of Akt phosphorylation in insulin-stimulated human A549 cells treated 2 hrs before insulin stimulation measured after 30 mins by ELISA Inhibition of Akt phosphorylation in insulin-stimulated human A549 cells treated 2 hrs before insulin stimulation measured after 30 mins by ELISA	[PMID: 22138309]
A549	IC₅₀	5.3 μM Compound: 2, OPP	Inhibition of Akt phosphorylation in human insulin-stimulated A549 cells incubated for 2 hrs prior to insulin-induction measured after 30 mins by ELISA Inhibition of Akt phosphorylation in human insulin-stimulated A549 cells incubated for 2 hrs prior to insulin-induction measured after 30 mins by ELISA	[PMID: 23415083]
A549	IC₅₀	7 μM Compound: 2, OPP	Cytotoxicity against human A549 cells after 24 hrs by FACS analysis Cytotoxicity against human A549 cells after 24 hrs by FACS analysis	[PMID: 22138309]
A549	IC₅₀	7 μM Compound: 2, OPP	Cytotoxicity against human A549 cells by flow cytometric analysis Cytotoxicity against human A549 cells by flow cytometric analysis	[PMID: 23415083]
ACHN	GI₅₀	4.56 μM Compound: Perifosine	Growth inhibition of human ACHN cells by sulforhodamine B assay Growth inhibition of human ACHN cells by sulforhodamine B assay	[PMID: 21543141]
ACHN	GI₅₀	4.56 μM Compound: Perifosine	Growth inhibition of human ACHN cells by SRB assay Growth inhibition of human ACHN cells by SRB assay	[PMID: 23266181]
ACHN	GI₅₀	4.56 μM Compound: Perifosine	Antiproliferative activity against human ACHN cells by SRB assay Antiproliferative activity against human ACHN cells by SRB assay	[PMID: 23567950]
ACHN	GI₅₀	4.56 μM Compound: Perifosine	Growth inhibition of human ACHN cells after 48 hrs by SRB assay Growth inhibition of human ACHN cells after 48 hrs by SRB assay	[PMID: 24095759]
HCT-15	GI₅₀	1.25 μM Compound: Perifosine	Growth inhibition of human HCT15 cells by sulforhodamine B assay Growth inhibition of human HCT15 cells by sulforhodamine B assay	[PMID: 21543141]
HCT-15	GI₅₀	1.25 μM Compound: Perifosine	Growth inhibition of human HCT15 cells by SRB assay Growth inhibition of human HCT15 cells by SRB assay	[PMID: 23266181]
HCT-15	GI₅₀	1.25 μM Compound: Perifosine	Antiproliferative activity against human HCT15 cells by SRB assay Antiproliferative activity against human HCT15 cells by SRB assay	[PMID: 23567950]
HCT-15	GI₅₀	1.25 μM Compound: Perifosine	Growth inhibition of human HCT15 cells after 48 hrs by SRB assay Growth inhibition of human HCT15 cells after 48 hrs by SRB assay	[PMID: 24095759]
MCF7	IC₅₀	13.3 μM Compound: 2, OPP	Cytotoxicity against human MCF7 cells after 24 hrs by FACS analysis Cytotoxicity against human MCF7 cells after 24 hrs by FACS analysis	[PMID: 22138309]
MCF7	IC₅₀	13.3 μM Compound: 2, OPP	Cytotoxicity against human MCF7 cells by flow cytometric analysis Cytotoxicity against human MCF7 cells by flow cytometric analysis	[PMID: 23415083]
MCF7	IC₅₀	75.8 μM Compound: OPP	Inhibitory concentration against MCF-7 cells gwoth Inhibitory concentration against MCF-7 cells gwoth	[PMID: 16190765]
MDA-MB-231	GI₅₀	2.86 μM Compound: Perifosine	Growth inhibition of human MDA-MB-231 cells by sulforhodamine B assay Growth inhibition of human MDA-MB-231 cells by sulforhodamine B assay	[PMID: 21543141]
MDA-MB-231	GI₅₀	2.86 μM Compound: Perifosine	Growth inhibition of human MDA-MB-231 cells by SRB assay Growth inhibition of human MDA-MB-231 cells by SRB assay	[PMID: 23266181]
MDA-MB-231	GI₅₀	2.86 μM Compound: Perifosine	Antiproliferative activity against human MDA-MB-231 cells by SRB assay Antiproliferative activity against human MDA-MB-231 cells by SRB assay	[PMID: 23567950]
MDA-MB-231	GI₅₀	2.86 μM Compound: Perifosine	Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay	[PMID: 24095759]
NCI-H23	GI₅₀	4.21 μM Compound: Perifosine	Growth inhibition of human NCI-H23 cells by sulforhodamine B assay Growth inhibition of human NCI-H23 cells by sulforhodamine B assay	[PMID: 21543141]
NCI-H23	GI₅₀	4.21 μM Compound: Perifosine	Growth inhibition of human NCI-H23 cells by SRB assay Growth inhibition of human NCI-H23 cells by SRB assay	[PMID: 23266181]
NCI-H23	GI₅₀	4.21 μM Compound: Perifosine	Antiproliferative activity against human NCI-H23 cells by SRB assay Antiproliferative activity against human NCI-H23 cells by SRB assay	[PMID: 23567950]
NCI-H23	GI₅₀	4.21 μM Compound: Perifosine	Growth inhibition of human NCI-H23 cells after 48 hrs by SRB assay Growth inhibition of human NCI-H23 cells after 48 hrs by SRB assay	[PMID: 24095759]
NUGC-3	GI₅₀	0.54 μM Compound: Perifosine	Growth inhibition of human NUGC3 cells by sulforhodamine B assay Growth inhibition of human NUGC3 cells by sulforhodamine B assay	[PMID: 21543141]
NUGC-3	GI₅₀	0.54 μM Compound: Perifosine	Growth inhibition of human NUGC3 cells by SRB assay Growth inhibition of human NUGC3 cells by SRB assay	[PMID: 23266181]
NUGC-3	GI₅₀	0.54 μM Compound: Perifosine	Antiproliferative activity against human NUGC3 cells by SRB assay Antiproliferative activity against human NUGC3 cells by SRB assay	[PMID: 23567950]
NUGC-3	GI₅₀	0.54 μM Compound: Perifosine	Growth inhibition of human NUGC3 cells after 48 hrs by SRB assay Growth inhibition of human NUGC3 cells after 48 hrs by SRB assay	[PMID: 24095759]
PC-3	GI₅₀	0.44 μM Compound: Perifosine	Growth inhibition of human PC3 cells by sulforhodamine B assay Growth inhibition of human PC3 cells by sulforhodamine B assay	[PMID: 21543141]
PC-3	GI₅₀	0.44 μM Compound: Perifosine	Growth inhibition of human PC3 cells by SRB assay Growth inhibition of human PC3 cells by SRB assay	[PMID: 23266181]
PC-3	GI₅₀	0.44 μM Compound: Perifosine	Antiproliferative activity against human PC3 cells by SRB assay Antiproliferative activity against human PC3 cells by SRB assay	[PMID: 23567950]
PC-3	GI₅₀	0.44 μM Compound: Perifosine	Growth inhibition of human PC3 cells after 48 hrs by SRB assay Growth inhibition of human PC3 cells after 48 hrs by SRB assay	[PMID: 24095759]
RBL-2H3	IC₅₀	5 μM Compound: 5	Inhibition of rat RBL2H3 cell granulation assessed as reduction of beta hexasaminidase release Inhibition of rat RBL2H3 cell granulation assessed as reduction of beta hexasaminidase release	[PMID: 20153565]

In Vitro

The IC₅₀ for growth of Ntv-a/LacZ cell lines is determined by MTT assay. When the cells are cultured for 48 hours in 10% FCS-supplemented media, the IC₅₀ for cells with constitutively active PDGF, Ras, or Akt signaling is similar and found to be ~45 μM^[1].Perifosine, a oral-bioavailable alkylphospholipid (ALK), on the cell cycle kinetics of immortalized keratinocytes (HaCaT) as well as head and neck squamous carcinoma cells. Proliferation is assessed by the incorporation of [³H]thymidine into cellular DNA. Exposure to Perifosine (0.1-30 μM) for 24 h results in a dose-dependent inhibition of [³H]thymidine uptake in all cell lines tested. The IC₅₀s for growth are between 0.6 and 8.9 μM, reaching IC₈₀s of ~10 μM. Perifosine blocks cell cycle progression of head and neck squamous carcinoma cells at G₁-S and G₂-M by inducing p21^WAF1, irrespective of p53 function, and may be exploited clinically because the majority of human malignancies harbor p53 mutations. Perifosine (20 μM) induces both G₁-S and G₂-M cell cycle arrest, together with p21^WAF1 expression in both p53 wild-type and p53^-/- clones^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Mice are identified with tumors by bioluminescence imaging and either treated them with 100 mg/kg Temozolomide, or 30 mg/kg Perifosine, or a combination with 100 mg/kg Temozolomide and 30 mg/kg Perifosine (Temozolomide+Perifosine) for 3 to 5 days. The mice are sacrificed and tumors analyzed histologically for cell proliferation by Ki-67 immunostaining. Ki-67 staining index is significantly reduced in mice treated with either Temozolomide (Ki-67 staining index=5.5±1.2%, n=4, P=0.0019) or Perifosine (Ki-67 staining index=3.2±1.1%, n=3, P=0.001) compared with Control, demonstrating the inhibitory effect on proliferation. Most importantly, the tumors treated with Temozolomide+Perifosine have the lowest Ki-67 staining index (1.7±1.2%, n=3, P=0.0005). The additional treatment with Perifosine results in a significantly lower proliferation rate than Temozolomide alone (P=0.0087)^[1]. Perifosine markedly decreases p-Akt from 10 min to 24 hours and subsequently, moderately decreased p-S6 from 1h to 24 h after injection^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 157716-52-4
Appearance Solid
Molecular Weight 461.66
Formula C₂₅H₅₂NO₄P
Color White to off-white
SMILES

[O-]P(OC1CC[N+](C)(CC1)C)(OCCCCCCCCCCCCCCCCCC)=O
Synonyms

KRX-0401; NSC 639966; D21266
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (19)

All WB

Sort by:

Journal Impact Factor

Cancer Res

Nerves Stimulates Crosstalk between Gastric Cancer and Group 3 Innate Lymphoid Cells to Enhance Immunosuppression. [Abstract]

2026 Jan 14. PMID: 41534088
Acta Pharm Sin B

A high-throughput Gaussia luciferase reporter assay for screening potential gasdermin E activators against pancreatic cancer. [Abstract]

2023 Oct;13(10):4253-4272. PMID: 37799380
Sci Transl Med

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]

2018 Jul 18;10(450):eaaq1093. PMID: 30021885
Int J Biol Sci

Ecological Trade-offs between Migration and Reproduction Are Mediated by the Nutrition-Sensitive Insulin-Signaling Pathway. [Abstract]

2016 Mar 30;12(5):607-16. PMID: 27143957
Cell Death Dis

METTL8 links mt-tRNA m3C modification to the HIF1α/RTK/Akt axis to sustain GBM stemness and tumorigenicity. [Abstract]

2024 May 14;15(5):338. PMID: 38744809
Cell Commun Signal

Targeting CCL2-CCR2 signaling pathway alleviates macrophage dysfunction in COPD via PI3K-AKT axis. [Abstract]

2024 Jul 17;22(1):364. PMID: 39014433
Int J Biol Macromol

Astrocyte-conditional knockout of MOB2 inhibits the phenotypic conversion of reactive astrocytes from A1 to A2 following spinal cord injury in mice. [Abstract]

2025 Jan 23:140289. PMID: 39863205
Biomed Pharmacother

JAK2 inhibitor protects the septic heart through enhancing mitophagy in cardiomyocytes. [Abstract]

2024 Aug 8:178:117279. PMID: 39121587
Biochem Pharmacol

ATF5 activates LPAR5 to enhance macrophage pro-inflammatory responses to exacerbate rheumatoid arthritis. [Abstract]

2026 May:247:117804. PMID: 41690415
J Cell Mol Med

17-β-Estradiol Protects Chondrocytes From Senescence and Ameliorates Osteoarthritis Progression via ERα-AKT-FOXO4 Pathway. [Abstract]

2026 Feb;30(3):e71018. PMID: 41677002
Cell Signal

Paeoniflorin-6'-O-benzene sulfonate inhibits keratinocyte proliferation by restoring GRK2-JAK1 colocalization in mouse model of psoriasis. [Abstract]

2025 Jul:131:111706. PMID: 40037425
Exp Cell Res

ACBD3 is up-regulated in gastric cancer and promotes cell cycle G1-to-S transition in an AKT-dependent manner. [Abstract]

2021 Sep 15;406(2):112752. PMID: 34332983
Mol Med Rep

Downregulation of miRNA‑328 promotes the angiogenesis of HUVECs by regulating the PIM1 and AKT/mTOR signaling pathway under high glucose and low serum condition. [Abstract]

2020 Aug;22(2):895-905. PMID: 32626978
Front Oncol

Rapamycin Antagonizes BCRP-Mediated Drug Resistance Through the PI3K/Akt/mTOR Signaling Pathway in mPRα-Positive Breast Cancer. [Abstract]

2021 Apr 12;11:608570. PMID: 33912444

Perifosine purchased from MedChemExpress. Usage Cited in: Front Oncol. 2021 Apr 12;11:608570. [Abstract]

The rescue test of PI3K/Akt/mTOR signaling in response to 17α-PG in MDA-MB-453/BCRP cells. The cells are starved for 48 h and then treated with 1,000 nM 17α-PG combined with siAkt or Perifosine.
Mol Immunol

Myocardial ischemia-reperfusion injury is probably due to the excessive production of mitochondrial ROS caused by the activation of 5-HT degradation system mediated by PAF receptor. [Abstract]

2023 Mar:155:27-43. PMID: 36682136
J Cell Biochem

Vascular endothelial growth factor enhances tendon-bone healing by activating Yes-associated protein for angiogenesis induction and rotator cuff reconstruction in rats. [Abstract]

2020 Mar;121(3):2343-2353. PMID: 31633245
SSRN

2025 Nov 25.
Masaryk University

2020 Jul.
Preprints

2020 Apr.

Solvent & Solubility

In Vitro:

H₂O : 100 mg/mL (216.61 mM; Need ultrasonic)

DMF : < 1 mg/mL (insoluble)

DMSO : < 1 mg/mL (insoluble or slightly soluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1661 mL

10.8305 mL

21.6610 mL

5 mM

0.4332 mL

2.1661 mL

4.3322 mL

10 mM

0.2166 mL

1.0830 mL

2.1661 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass

Concentration

Volume

Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 50 mg/mL (108.30 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage
mg/kg
Animal Weight (Per Animal)
g
Dosing Volume (Per Animal)
μL
Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Protocol

Kinase Assay^[2]

Exponentially growing cells (HN12, HN30, and HaCaT) are lysed, and 500 μg of total cellular protein are used to immunoprecipitate active cdc2 and cdk2 complexes. After capturing with gammabind G Sepharose and subsequent washes, the active immune complexes are assessed for activity in the presence of increasing concentrations of Perifosine (0.1-30 μM) or flavopiridol (300 nM) in the kinase assay buffer containing [γ-³²P]ATP (3000 Ci/mmol) and 0.2 mg/mL histone H1, 25 μM ATP. Reactions are incubated at 37°C for 30 min and terminated by the addition of SDS-gel loading buffer, resolved in SDS-PAGE, and dried gels are subjected to autoradiography and phosphorimaging^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[2]

Cell proliferation studies by measuring the uptake of [³H]thymidine is performed. Briefly, HNSCC and HaCaT cells (1-2×10⁴/well) are grown overnight in 24-well plates and exposed to either Perifosine (0.1-30 μM) or PBS (control). After treatment (24-48 h), cells are pulsed with [³H]thymidine (1 μCi/well) for 4-6 h, fixed (5% trichloroacetic acid), and solubilized (0.5 M NaOH) before scintillation counting. Experiments are performed in triplicates^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]^[3]

Mice^[1]
Drug treatment of tumor-bearing mice. Image-positive Ef-luc Ntv-a mice are treated daily with i.p. administration of buffer alone as a control, or i.p. administration of 100 mg/kg Temozolomide, or oral administration of 30 mg/kg Perifosine, or a combination with Perifosine and Temozolomide for 3 to 5 days. The mean doses of the treatments are: Control, 5 (all five); Temozolomide, 3.75 (three to five); Perifosine, 3.75 (three to four); and Perifosine+Temozolomide, 3 (all three). Control buffer solution consisted of 5% DMSO and 1% Tween 80 in distilled water.
Rats^[3]
To further determine whether the paradoxical effect of rapamycin on S6 phosphorylation is related to upstream signals of Akt-mTOR, rats are treated with Perifosine (20 mg/kg, ip, once), an Akt inhibitor, 30 min before rapamycin administration. Rats are sacrificed 1 h or 6 h after rapamycin injection.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (275 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Momota H, et al. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res, 2005, 65(16), 7429-7435. [Content Brief]

[2]. Vyomesh Patel, et al. Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest. Cancer Res, 2002, 62(5), 14 [Content Brief]

[3]. Chen L, et al. Rapamycin has paradoxical effects on S6 phosphorylation in rats with and without seizures. Epilepsia. 2012 Nov;53(11):2026-33. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	2.1661 mL	10.8305 mL	21.6610 mL	54.1524 mL
	5 mM	0.4332 mL	2.1661 mL	4.3322 mL	10.8305 mL
	10 mM	0.2166 mL	1.0830 mL	2.1661 mL	5.4152 mL
	15 mM	0.1444 mL	0.7220 mL	1.4441 mL	3.6102 mL
	20 mM	0.1083 mL	0.5415 mL	1.0830 mL	2.7076 mL
	25 mM	0.0866 mL	0.4332 mL	0.8664 mL	2.1661 mL
	30 mM	0.0722 mL	0.3610 mL	0.7220 mL	1.8051 mL
	40 mM	0.0542 mL	0.2708 mL	0.5415 mL	1.3538 mL
	50 mM	0.0433 mL	0.2166 mL	0.4332 mL	1.0830 mL
	60 mM	0.0361 mL	0.1805 mL	0.3610 mL	0.9025 mL
	80 mM	0.0271 mL	0.1354 mL	0.2708 mL	0.6769 mL
	100 mM	0.0217 mL	0.1083 mL	0.2166 mL	0.5415 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Perifosine

Apoptosis Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Covalent Screening Library

Differentiation Inducing Compound Library

Lipid Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Rare Diseases Drug Library

Anti-Colorectal Cancer Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Perifosine

All Akt Isoforms

Biological Activity

Chemical Information

Publications (19)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Perifosine Related Classifications

Cat. No.: HY-50909